Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Inclusion Criteria: * HIV-1 infection * Postmenopausal at study entry with agreement not to participate in assisted reproductive technology in the future. * CD4+ cell count greater than 300 cells/uL obtained within 90 days prior to study entry. * Continuous antiretroviral therapy (ART) for at least 2 years prior to enrollment with no known interruption in therapy for greater than 7 days within 90 days prior to study entry. * Plasma HIV-1 RNA level of less than 20 copies/mL obtained by Roche HIV-1 viral load assay or less than 40 copies/mL obtained by the Abbott assay, within 90 days prior to study entry. * Ability and willingness of potential participant to provide written informed consent. Exclusion Criteria: * History of venous thromboembolism. * History of stroke. * Known history of hypercoagulable state. * Tobacco smoking or e-cigarette use within 90 days prior to study entry. * History of any malignancy requiring systemic chemotherapy or systemic immunotherapy. * History of endometrial or breast cancer or known genetic testing with BRCA positive results indicating an increased risk for breast and ovarian cancer. * Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, or investigational therapy within 60 days prior to study entry. * Any systemic hormonal therapy defined as oral or injectable contraceptives, estrogen and combined estrogen-progesterone replacement therapy in the prior 12 months, or a hormone containing intrauterine device …